Début de l'essai clinique de phase 1 de FAIR

A Phase I clinical trial for FLAMOD, a novel treatment designed to boost the body’s immune defenses against respiratory infections, has started at the Clinical Investigation Centre of Tours University Hospital in France. The trial, named NEBUFLAG, is a major achievement of the EU-granted FAIR project (https://www.fair-flagellin.eu), that prepared during 5 years for this clinical milestone. FAIR Coordinator Dr. Jean-Claude Sirard acknowledges the consortium's efforts: “FAIR partners’ dedication from preclinical studies, toxicology and modeling to patient stratification in the Netherlands, brings closer to personalized treatment for vulnerable patients.”
Unlike conventional antibiotics, FLAMOD that was developed by CIIL, works by stimulating the immune system rather than directly attacking bacteria. Administered via aerosol with an Aerogen mesh-nebulizer, the treatment targets lung tissue to trigger a localized immune response, avoiding systemic side effects. It is intended to complement standard antibiotics and improve their effectiveness, especially important in the context of rising antibiotic resistance. FLAMOD is derived from flagellin, a natural bacterial protein, and represents a new therapeutic strategy for drug-resistant bacterial pneumonia. This approach could be a game changer in addressing antibiotic resistance. Respiratory infections remain the third leading cause of death globally, responsible for around 3 million deaths annually.,
Prof. Antoine Guillon, principal investigator of the clinical trial at Tours Hospital, and Dr. Valérie Gissot, Head of the Clinical Investigation Centre, highlighted the unique development path of FLAMOD. This innovation was driven by academic researchers and clinicians from concept to clinical trial, and made possible through EU funding.

Voir plus